Maxim Group assumed coverage on shares of GeoVax Labs (OTCMKTS:GOVX) in a research note issued to investors on Thursday morning, Analyst Ratings Network reports. The firm issued a buy rating and a $8.00 price objective on the biotechnology company’s stock.
GOVX stock opened at $2.73 on Thursday. GeoVax Labs has a 1 year low of $2.30 and a 1 year high of $60.00. The stock has a 50-day simple moving average of $2.97 and a 200-day simple moving average of $1.18.
In other news, CFO Mark Reynolds bought 60,184 shares of the firm’s stock in a transaction dated Tuesday, September 29th. The stock was bought at an average price of $5.00 per share, for a total transaction of $300,920.00. Also, Director Randal D. Chase bought 16,613 shares of the firm’s stock in a transaction dated Tuesday, September 29th. The stock was purchased at an average price of $5.00 per share, with a total value of $83,065.00. In the last 90 days, insiders have acquired 158,667 shares of company stock valued at $793,335.
GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers.
Further Reading: What Are Treasury Bonds?
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.